We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA: Drugmakers Should Determine Endocrine Effect Before Starting Clinical Trials
FDA: Drugmakers Should Determine Endocrine Effect Before Starting Clinical Trials
Before wasting time and money on a clinical trial, sponsors should determine whether additional preclinical studies are needed to rule out a drug candidate’s potential for endocrine-related adverse effects, the FDA says.